You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
| Title |
A novel haplo-identical adoptive CTL therapy as a treatment for EBV-associated lymphoma after stem cell transplantation
|
|---|---|
| Published in |
Cancer Immunology, Immunotherapy, November 2009
|
| DOI | 10.1007/s00262-009-0789-1 |
| Pubmed ID | |
| Authors |
Michael Uhlin, Mantas Okas, Jens Gertow, Mehmet Uzunel, Torkel B. Brismar, Jonas Mattsson |
| Abstract |
Epstein-Barr virus (EBV)-related malignancies such as post-transplant lymphoproliferative disease (PTLD) are severe complications after allogeneic stem cell transplantation and solid-organ transplantation. In immunosuppressed transplant recipients, the activity of EBV-specific CTLs are often decreased or absent which leads to an increased risk of developing PTLD. If primary treatment modalities of PTLD fail, the most efficient way of treating the malignancy is adopting EBV-specific CTLs from the donor or, more recently, third-party donors. However, both are time consuming and expensive and often it is too late to administer cells to the patient. We have for the first time, using a rapid isolation protocol of EBV-specific T cells, treated and cured a patient suffering from PTLD with multiple-associated tissue lesions, using her haplo-identical mother as a donor. This treatment approach paves way for a new possibility to within-days treat patients with life-threatening EBV-associated malignancies. |
Mendeley readers
The data shown below were compiled from readership statistics for 32 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 3% |
| Unknown | 31 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 5 | 16% |
| Student > Ph. D. Student | 4 | 13% |
| Student > Bachelor | 3 | 9% |
| Other | 3 | 9% |
| Unspecified | 3 | 9% |
| Other | 7 | 22% |
| Unknown | 7 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 9 | 28% |
| Agricultural and Biological Sciences | 4 | 13% |
| Unspecified | 3 | 9% |
| Immunology and Microbiology | 3 | 9% |
| Biochemistry, Genetics and Molecular Biology | 2 | 6% |
| Other | 4 | 13% |
| Unknown | 7 | 22% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 September 2012.
All research outputs
#7,454,951
of 22,790,780 outputs
Outputs from Cancer Immunology, Immunotherapy
#1,037
of 2,881 outputs
Outputs of similar age
#33,546
of 93,378 outputs
Outputs of similar age from Cancer Immunology, Immunotherapy
#8
of 18 outputs
Altmetric has tracked 22,790,780 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,881 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.2. This one is in the 37th percentile – i.e., 37% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 93,378 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 20th percentile – i.e., 20% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 18 others from the same source and published within six weeks on either side of this one. This one is in the 11th percentile – i.e., 11% of its contemporaries scored the same or lower than it.